Stocks · News reference
Canaccord Genuity Initiates Coverage On CareDx with Buy Rating, Announces Price Target of $65
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Maintains Buy on CareDx, Raises Price Target to $74
BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $60 to $74.
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.
8-K/A filing — CareDx, Inc. (CDNA)
Filed: 2026-09-16 AccNo: 0001217234-26-000052 Size: 10 MB Item 2.01: Completion of Acquisition or Disposition of Assets Item 9.01: Financial Statements and Exhibits